Financings in Brief: KeraVision
This article was originally published in The Gray Sheet
Executive SummaryKeraVision: Begins trading on NASDAQ under the symbol "KERA" following completion of an initial public offering of 3.6 mil. shares for $13.50 each. KeraVision filed a registration statement for the IPO in June ("The Gray Sheet" June 12, I&W-8)...
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.